Debio 0432

Debio 0432 is a potent and selective small molecule inhibitor of ubiquitin-specific protease 1 (USP1), an emerging target in the DNA damage repair (DDR) pathway for cancer therapy. By inhibiting USP1, Debio 0432 disrupts the deubiquitination of key proteins involved in DNA repair, such as FANCI, FANCD2 (critical for interstrand crosslink repair), and PCNA (important for translesion synthesis). This leads to forced arrest of DDR and induces apoptosis in tumor cells—particularly those with underlying defects in DNA repair genes like BRCA1. The drug has demonstrated antitumor activity both as monotherapy and in combination with PARP inhibitors across various preclinical models, including BRCA-mutant breast cancer and homologous recombination proficient ovarian cancer. Originally discovered by Forma Therapeutics (acquired by Novo Nordisk) and now licensed to Debiopharm, Debio 0432 is currently in late-stage preclinical development targeting multiple solid tumor types[1][2][5][7].

Other names

FT 3171FT3171FT-3171